GxPinnacle Logo

Pharmacovigilance Regulatory Expectations

What Do Inspectors Check for Pharmacovigilance KPI Escalation and CAPA?

Pharmacovigilance systems must escalate KPI deviations and implement corrective and preventive actions (CAPA). Regulators expect organisations to investigate performance failures, document root cause, implement CAPAs, and demonstrate effectiveness of actions taken.

Founders, CEOs & MDsPV LeadsQA/ComplianceScientists tasked with documentation

The short version

What teams need to understand

  • KPI deviations must trigger escalation, investigation, and corrective action within the pharmacovigilance system.
  • Organisations should define thresholds that determine when escalation is required.
  • Root cause analysis must be performed for significant performance failures.
  • Corrective and preventive actions (CAPA) should be documented, implemented, and tracked.
  • CAPA effectiveness must be monitored to ensure issues are resolved.
  • Inspection-ready evidence should demonstrate that KPI deviations lead to structured and effective remediation.

Regulatory expectation

What regulators expect

Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.

  • KPI deviations must be identified and escalated.
  • Root cause analysis must be performed for significant issues.
  • CAPAs must be defined, implemented, and tracked.
  • Effectiveness of CAPAs must be verified.
  • PV systems must demonstrate continuous improvement through CAPA processes.

Why it matters

What this means in practice

Inspectors assess whether pharmacovigilance systems respond appropriately to KPI deviations through escalation, investigation, and CAPA processes. They typically review deviation records, root cause analysis, CAPA documentation, and evidence that corrective actions are implemented and effective.

Questions this page answers

What happens when pharmacovigilance KPIs fall below target?
How should KPI deviations be escalated in PV?
What CAPA processes do inspectors expect in pharmacovigilance?
How do inspectors assess CAPA effectiveness?
What triggers CAPA in pharmacovigilance systems?
How are KPI failures investigated in PV?
What evidence is required for CAPA during inspections?
How should pharmacovigilance CAPA be managed?
What is expected for deviation handling in PV systems?
How do inspectors verify CAPA processes?

Inspection evidence

Evidence teams should be able to show

Deviation and Escalation Records

  • Documentation of KPI breaches or deviations
  • Defined escalation thresholds and triggers
  • Escalation records to PV leadership or governance committees
  • Evidence of issue recognition and classification

Root Cause Analysis Documentation

  • Investigation reports for KPI deviations
  • Identification of underlying causes
  • Use of structured root cause methodologies (e.g. 5 Whys, Fishbone)
  • Documentation linking root cause to corrective actions

CAPA Management Records

  • Defined CAPA plans addressing identified issues
  • Assignment of CAPA owners
  • Defined timelines for CAPA implementation
  • Status tracking of CAPA activities

CAPA Effectiveness Checks

  • Evidence that corrective actions resolved the issue
  • Monitoring of KPI performance after CAPA implementation
  • Follow-up reviews confirming no recurrence
  • Documentation of CAPA closure decisions

Regulatory Basis (Primary Sources)

  • GVP Module I - pharmacovigilance systems must include deviation management and CAPA processes
  • GVP Module IV - PV audit findings and CAPA expectations
  • ICH E2D - monitoring and response to safety system performance issues
  • ICH E2E - pharmacovigilance system risk management and improvement
  • MHRA GPvP guidance - expectations for deviation handling and CAPA
  • FDA pharmacovigilance guidance - corrective action and compliance management

Typical Inspection Questions (What Inspectors Ask)

  • What happens when KPI performance falls below target?
  • Show me CAPA records related to KPI deviations.
  • How do you investigate performance issues?
  • How do you ensure CAPAs are effective?
  • Show evidence that issues identified through KPIs are resolved.

Common failure patterns

KPI deviations are identified but not escalated.
Root cause analysis is superficial or not documented.
CAPAs are defined but not implemented effectively.
No evidence of CAPA effectiveness checks.
Recurring issues indicate ineffective CAPA processes.

What good looks like

  • Clear escalation of KPI deviations based on defined thresholds.
  • Structured root cause analysis linking issues to corrective actions.
  • CAPAs are documented, assigned, and tracked to completion.
  • Effectiveness of CAPAs is verified through performance monitoring.
  • Continuous improvement demonstrated through resolved issues and stable KPI performance.

How teams operationalise it

  • Define escalation thresholds for KPI deviations.
  • Ensure KPI breaches trigger investigation and escalation.
  • Perform structured root cause analysis for identified issues.
  • Develop CAPA plans with defined owners and timelines.
  • Track CAPA implementation and completion.
  • Verify CAPA effectiveness through KPI monitoring.

From expectation to working control

Find the documentation that supports this work

Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.

Browse pharmacovigilance toolkitsView related toolkit

Frequently asked questions

What triggers CAPA in pharmacovigilance systems?

CAPA is typically triggered when KPI performance falls below defined thresholds or when compliance risks are identified.

What is expected for root cause analysis in PV?

Root cause analysis should identify the underlying cause of performance issues and link directly to corrective actions.

Do inspectors review CAPA records?

Yes. Inspectors frequently request CAPA documentation to confirm that issues are investigated and resolved.

How do organisations demonstrate CAPA effectiveness?

Effectiveness is demonstrated by improved KPI performance and absence of recurring issues after CAPA implementation.

What happens if KPI deviations are not addressed?

Failure to address KPI deviations may result in inspection findings and regulatory action.

How do inspectors verify CAPA processes?

Inspectors review deviation records, root cause analysis, CAPA plans, and evidence of effectiveness to confirm compliance.

Source boundary

Regulatory sources

These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.

European Medicines Agency (EMA)

  • Good pharmacovigilance practices (GVP)

    View source

  • Guideline on good pharmacovigilance practices (GVP) - Module I

    View source

FDA

ICH

MHRA